Symrise presents clinical evidence: Symrise stock sits 1.01 percent below high

Published on 10/22/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Symrise presented clinical evidence on October 21, 2026. Symrise stock costs EUR 101.35 on October 22, 2026, 0.35 percent above Xetra close.

Clinical evidence and reporting date

Symrise presented clinical findings on October 21, 2026, covering skin and digestive health.
Fiscal year 2025 revenue reached EUR 4.929 billion, while the adjusted EBITDA margin was 21.90 percent.
Symrise stock trades at EUR 101.35 at 9:47 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.35 percent above the Xetra close of October 21, 2026.
Symrise will publish its January to September 2026 interim report on October 28, 2026.

Bauhaus-Plakat mit geometrischen Formen und Sektor-Schriftzug CHEMIE, Symrise AG DE000SYM9999 — Symrise AG (DE000SYM9999) Bauhaus-Poster zeigt geometrische Formen, Parfümflakon und Text CHEMIE stilisiert, Illustration mit AI erstellt.

Symrise AG (DE000SYM9999) was trading at EUR 101.35 at Lang & Schwarz on October 22, 2026, at 9:47 a.m. CEST, up 0.35 percent versus the Xetra close of October 21, 2026, at EUR 101.00. On October 21, Symrise presented new clinical evidence on skin and digestive health at SupplySide Global 2026, according to Symrise.

Health research broadens the story

The latest company update places health applications alongside Symrise's established flavors and fragrances activities. The investor-relations page describes the group as a supplier of cosmetic, pharmaceutical, dietary supplement and pet-food ingredients, giving the clinical work a direct link to several customer markets.

The financial baseline is also concrete. In fiscal year 2025, Symrise reported revenue of EUR 4.929 billion and organic growth of 2.80 percent. Its adjusted EBITDA margin was 21.90 percent, according to the company's investor-relations information.

What does the buyback add?

Capital allocation provides a second current reference point. Between October 12 and October 16, 2026, Symrise acquired 137,000 shares, bringing cumulative repurchases since February 2, 2026, to 4,655,518 shares, according to EQS News on October 19, 2026.

Three dates frame the next move

Symrise is scheduled to publish its interim group report for January to September 2026 on October 28, 2026. The same date also lists a virtual management roadshow, according to the company's investor-relations calendar. The report should give investors the next quantified view of organic growth, margin delivery and demand across the group's businesses.

Stock holds near its yearly high

At EUR 101.35, the stock was EUR 1.03 below its 52-week high of EUR 102.38 and within the quoted 52-week range of EUR 64.70 to EUR 102.38. The market capitalization was EUR 13.9 billion as of October 22, 2026. The combination of clinical evidence, ongoing repurchases and an imminent reporting date gives the share several company-specific reference points.

Symrise stock was trading at EUR 101.35 at Lang & Schwarz on October 22, 2026, at 9:47 a.m. CEST, 0.35 percent above the Xetra close of October 21, 2026, at EUR 101.00. The further course of trading is shown by the continuously updated real-time quote of Symrise stock.